Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Subscribe To Our Newsletter & Stay Updated